https://www.selleckchem.com/pr....oducts/s-2-hydroxysu
001). The 8-year PFS estimates in the BC and BM arms were 54.1% (95% CI 40.9%-71.5%) and 64.4% (95% 51.8%-79.0%), respectively. PFS was significantly longer for transplanted patients on 50403 compared with those on 59909. PFS and OS were significantly better for those who were MRD-negative post-induction. High risk proliferation signature was associated with adverse outcome. Both BM and BC were efficacious and tolerable, although toxicity was significant. The comparison between studies 50403 and 59909 with long-term fol
Like
Comment
Share
